MacMillan catalyst was modified with imidazolium ionic liquid by ester linkage and acts as recoverable and reusable catalyst for asymmetricDiels–Alder reactions. A Diels–Alder reaction between cyclopentadiene and crotonaldehyde was carried out using MacMillan catalyst modified with ionic liquid (5 mol%) using trifluoroacetic acid (5 mol%) as co-catalyst in acetonitrile–water (95 : 5) at room temperature
Chiral Imidazolidin‐4‐one with catalytic amount of Dicationic ionic liquid act as a recoverable and reusable Organocatalyst for asymmetric Diels‐Alder reaction
the asymmetric Diels‐Alder reaction in the presence of catalytic amount of dicationic ionicliquid and trifluoroacetic acid as a co‐catalyst. The Diels‐Alder reaction between model substrate cyclopentadiene and crotonaldehyde gave the product in 95% conversion and 87% ee of the endo‐product. The catalyst was shown better reusability when the 20 mol% of dicationic ionicliquid was used and catalyst was
From Immobilization to Catalyst Use: A Complete Continuous‐Flow Approach Towards the Use of Immobilized Organocatalysts
作者:Pedro H. R. Oliveira、Bruno M. S. Santos、Raquel A. C. Leão、Leandro S. M. Miranda、Rosane A. S. San Gil、Rodrigo O. M. A. Souza、Fernanda G. Finelli
DOI:10.1002/cctc.201901129
日期:2019.11.21
organocatalyst under a complete continuous‐flow approach, showing the impact of this method on the morphology, structure and lifetime of the organocatalyst. The first generation MacMillan's organocatalyst was prepared from L‐phenylalanine and immobilized in silica through a carbamate linkage under batch and continuous‐flowconditions. We also evaluated the performance of both batch and continuous‐flow organocatalysts
The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.
The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.